Tema Etfs LLC Takes Position in Arvinas, Inc. $ARVN

Tema Etfs LLC bought a new position in Arvinas, Inc. (NASDAQ:ARVN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 48,801 shares of the company’s stock, valued at approximately $579,000. Tema Etfs LLC owned approximately 0.08% of Arvinas at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its position in Arvinas by 9.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 46,574 shares of the company’s stock valued at $552,000 after purchasing an additional 4,074 shares during the last quarter. SG Americas Securities LLC boosted its stake in Arvinas by 104.3% in the fourth quarter. SG Americas Securities LLC now owns 78,164 shares of the company’s stock worth $927,000 after purchasing an additional 39,908 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Arvinas by 475.5% during the third quarter. JPMorgan Chase & Co. now owns 214,779 shares of the company’s stock worth $1,830,000 after purchasing an additional 177,460 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in shares of Arvinas in the third quarter valued at $291,000. Finally, Jacobs Levy Equity Management Inc. increased its stake in shares of Arvinas by 26.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 222,480 shares of the company’s stock valued at $1,896,000 after buying an additional 46,238 shares in the last quarter. 95.19% of the stock is currently owned by institutional investors.

Insider Activity at Arvinas

In related news, insider Noah Berkowitz sold 6,435 shares of the business’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $11.10, for a total transaction of $71,428.50. Following the completion of the sale, the insider directly owned 202,503 shares of the company’s stock, valued at $2,247,783.30. The trade was a 3.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director John G. Houston sold 35,297 shares of the stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $13.21, for a total transaction of $466,273.37. Following the completion of the transaction, the director owned 1,122,183 shares in the company, valued at $14,824,037.43. This represents a 3.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 63,864 shares of company stock worth $802,443 over the last 90 days. Insiders own 4.73% of the company’s stock.

Arvinas Stock Down 4.2%

Arvinas stock opened at $10.85 on Friday. The business’s 50-day simple moving average is $12.40 and its 200 day simple moving average is $11.32. The stock has a market cap of $693.97 million, a price-to-earnings ratio of -8.48 and a beta of 1.97. Arvinas, Inc. has a 12-month low of $5.90 and a 12-month high of $14.51.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.55). Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.The firm had revenue of $9.50 million for the quarter, compared to the consensus estimate of $37.26 million. During the same period in the prior year, the firm posted ($0.63) earnings per share. The business’s revenue for the quarter was down 84.0% compared to the same quarter last year. As a group, sell-side analysts expect that Arvinas, Inc. will post -3.81 EPS for the current year.

Analyst Ratings Changes

ARVN has been the topic of several research reports. Truist Financial set a $10.00 price target on shares of Arvinas in a research report on Wednesday, March 18th. Wedbush raised their price objective on shares of Arvinas from $9.00 to $11.00 and gave the company a “neutral” rating in a research report on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arvinas in a research note on Monday, December 22nd. BTIG Research upped their target price on shares of Arvinas from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, March 19th. Finally, Barclays raised their price target on shares of Arvinas from $16.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Ten equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.88.

Arvinas Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.